Flavopiridol methods and compositions for HIV therapy

US6660750B2 · kind B2 · utility

Assignees

• University of Iowa Research Foundation · US
• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• David Price · Knoxville, US
• Adrian Senderowicz · Somerville, US

Key dates

• Filing date: Feb 15, 2001
• Grant date: Dec 9, 2003
• Expiry date: Feb 28, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is the unexpected discovery that flavopiridol binds tightly to the transcription elongation factor, P-TEFb and dramatically inhibits its activity. As P-TEFb is required for HIV propagation and replication, this invention provides new methods, compositions and kits for the effective treatment of HIV infections and AIDS using flavopiridol, both alone and combination with other therapies.